

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **ADMISSION OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" TO THE "LIST OF MARKETED DRUGS OF CHINA"**

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group's "Paclitaxel for Injection (albumin-bound)" has been admitted to the "List of Marketed Drugs of China".

The "List of Marketed Drugs of China" published by the China Drug Administration includes information of innovative drugs, improved new drugs, generic drugs under the new chemical drug class registration and drugs passing the consistency of quality and efficacy evaluation which have been approved for marketing; reference listed drugs and reference standards of specific generic drugs; and designated generic drugs which can substitute for the originator drugs. The China Drug Administration will include drugs which are approved under the new class registration and drugs which have passed the consistency of quality and efficacy evaluation into the "List of Marketed Drugs of China".

The Group is the first enterprise which has obtained approval for the production of paclitaxel for injection (albumin-bound) under the new chemical drug class registration in China. Direct admission to the "List of Marketed Drugs in China" and permission to be marked as "consistency evaluation

passed” indicate that the drug is consistent with its originator drug in terms of quality and efficacy and is available as a clinical alternative for the originator drug, providing a medication option of good quality and competitive price for patients.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 4 June 2018

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*